High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.42M
-88.55%
-0.630
-17.12%
2.35M
-22.34%
-0.637
-27.56%
2.35M
+93.97%
-0.575
-28.13%
Estimates Revision
The market is revising Downward the revenue expectations for Vir Biotechnology, Inc. (VIR) for FY2025, with the revenue forecasts being adjusted by -42.46% over the past three months. During the same period, the stock price has changed by 28.65%.
Revenue Estimates for FY2025
Revise Downward
-42.46%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+6.19%
In Past 3 Month
Stock Price
Go Up
+28.65%
In Past 3 Month
7 Analyst Rating
Wall Street analysts forecast VIR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VIR is 17.67 USD with a low forecast of 12.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.780
Low
12.00
Averages
17.67
High
31.00
Current: 6.780
Low
12.00
Averages
17.67
High
31.00
Evercore ISI
Outperform
initiated
$12
2025-09-03
Reason
Evercore ISI
Price Target
$12
2025-09-03
initiated
Outperform
Reason
Evercore ISI initiated coverage of Vir Biotechnology with an Outperform rating and $12 price target. The firm sees a "compelling asymmetric setup" for the shares. Investors are underappreciating how quickly the Vir story can turn around, the analyst tells investors in a research note. Evercore believes the company has a "differentiated" oncology pipeline and pivotal-stage rare disease asset with validated biology. However, the stock trade below its cash position, the firm points out.
BofA
Neutral -> Buy
upgrade
$12 -> $14
2025-08-27
Reason
BofA
Price Target
$12 -> $14
2025-08-27
upgrade
Neutral -> Buy
Reason
BofA upgraded Vir Biotechnology to Buy from Neutral with a price target of $14, up from $12.
BofA
Alec Stranahan
Neutral -> Buy
upgrade
$12 -> $14
2025-08-27
Reason
BofA
Alec Stranahan
Price Target
$12 -> $14
2025-08-27
upgrade
Neutral -> Buy
Reason
As previously reported, BofA analyst Alec Stranahan upgraded Vir Biotechnology to Buy from Neutral with a price target of $14, up from $12, arguing that the market is underestimating the potential for its asset for treatment of severe liver disease caused by hepatitis delta virus. There also seems to be minimal value attributed to T-cell engager oncology programs, despite initial proof-of-concept data, the analyst tells investors.
Raymond James
initiated
$12
2025-07-11
Reason
Raymond James
Price Target
$12
2025-07-11
initiated
Reason
Raymond James initiated coverage of Vir Biotechnology with an Outperform rating and $12 price target.
Raymond James
Sean McCutcheon
Outperform
initiated
$12
2025-07-11
Reason
Raymond James
Sean McCutcheon
Price Target
$12
2025-07-11
initiated
Outperform
Reason
Raymond James analyst Sean McCutcheon initiated coverage of Vir Biotechnology with an Outperform rating and $12 price target. Vir's VIR-5500 shows "compelling" early Phase 1 data in heavily treated metastatic castration-resistant prostate cancer patients, and VIR-5500 is well-positioned to capture share in the large and growing mCRPC market, the analyst tells investors in a research note. The firm's constructive view is balanced by competitive headwinds in prostate cancer, as well as the company's high burn rate and need for additional financing to bring VIR-5500 through pivotal studies.
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$110 -> $15
2025-05-20
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$110 -> $15
2025-05-20
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Vir Biotechnology to $15 from $110 and keeps a Buy rating on the shares. The company's updated 24-week off-treatment data from the Phase 2 program did not meet functional cure thresholds that would be needed to support a Phase 3 investment in the absence of a global partner in chronic hepatitis B virus, the analyst tells investors in a research note. The firm believes chronic hepatitis delta virus infection is now Vir's clear lead value driver in hepatitis.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Vir Biotechnology Inc (VIR.O) is -2.77, compared to its 5-year average forward P/E of -6.21. For a more detailed relative valuation and DCF analysis to assess Vir Biotechnology Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-6.21
Current PE
-2.77
Overvalued PE
10.54
Undervalued PE
-22.97
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-2.65
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
9.64
Undervalued EV/EBITDA
-14.95
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
26.60
Current PS
0.00
Overvalued PS
50.61
Undervalued PS
2.59
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 3690.48% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
VIR News & Events
Events Timeline
(ET)
2025-11-09
19:18:16
Vir Biotechnology Reveals Week 48 Endpoint Analysis Results from Phase 2 SOLSTICE Study
2025-11-05 (ET)
2025-11-05
16:42:28
Vir Biotechnology Announces Q3 Earnings Per Share of $1.17, Exceeding Consensus Estimate of $0.86
2025-11-03 (ET)
2025-11-03
08:07:22
Vir Biotechnology finishes participant enrollment for ECLIPSE 1 trial
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/95d522a1f572b6f3ee582b020549e6032de19b54f94b34e95cba24efd7deefb5.png)
Preview
9.0
11-10NewsfilterVir Biotechnology Reveals Phase 2 Data at AASLD The Liver Meeting® and in NEJM, Showing High Undetectable HDV RNA Rates and Positive Safety Profile for Tobevibart and Elebsiran Combination
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/9a76a24c8d89b6bb64415f4b4b53d116ffc508840931b7f628a932152e042060.png)
Preview
9.0
11-10Yahoo FinanceVir Biotechnology Reveals Phase 2 Data at AASLD The Liver Meeting® and in NEJM, Showcasing High Undetectable HDV RNA Rates and Positive Safety Profile for Tobevibart & Elebsiran Combination
Preview
1.0
11-07NewsfilterVir Biotechnology to Take Part in the Jefferies 2025 London Healthcare Conference
Sign Up For More News
People Also Watch
FAQ
What is Vir Biotechnology Inc (VIR) stock price today?
What is Vir Biotechnology Inc (VIR)'s business?
What is the price predicton of VIR Stock?
What is Vir Biotechnology Inc (VIR)'s revenue for the last quarter?
What is Vir Biotechnology Inc (VIR)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Vir Biotechnology Inc (VIR)'s fundamentals?
How many employees does Vir Biotechnology Inc (VIR). have?